International Cellular Medicine Society Grants First Worldwide Accreditation to Tijuana Clinical Trial

Share Article

Regenerative Medicine Institute, Mexico has been granted full accreditation for its clinical stem cell trials

“The clinic understood that patient safety can only be assured through strict evaluation and rigorous oversight."

The International Cellular Medicine Society (ICMS), a professional medical association dedicated to patient safety through the strict evaluation of cell-based therapies and the rigorous oversight of medical facilities and clinics, has granted the status of “Accredited” to the Regenerative Medicine Institute (RMI) of Tijuana, Mexico.

“We are pleased that RMI undertook this process,” says David Audley, executive director of the ICMS. “The clinic understood that patient safety can only be assured through strict evaluation and rigorous oversight. From day one they have embraced the transparency that this program requires.”

RMI is the first clinic to achieve this status under the ICMS Accreditation Program. The clinic has undergone two separate site audits as well as an institutional review board review evaluation. Most importantly, the clinic has placed in excess of 50 patients into the Treatment Registry for long-term outcome tracking. “The safety profile has been excellent,” continued Audley. “We have tracked patients over at least two follow-ups and a minimum of six months and not seen a single cell-related adverse event.”

The ICMS is currently evaluating nearly a dozen clinics worldwide. Accreditation is based upon the Guidelines for the Practice of Cell-Based Medicine developed and published by the ICMS. Key components of these guidelines are the ethical recruitment of patients, proper consent of patients and compliance with local laws and regulations in the treatment of patients.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Visit website